The aim of the first trials will be to show that these vaccine candidates are safe and can reduce the burden of infectious mono nucleosis. This illness causes symptoms including extreme fatigue and fever, and affects 30 to 50 % of people who contract e b v for the first time as teen ages or young adults. On average it takes around ten years for a vaccine to run the clinical trial gauntlet. After approval, observational data would take many more years to accumulate.
Results from a huge epidemiological study found that infection by the Epstein-Barr virus increases the risk of developing multiple sclerosis 32-fold. This result, combined with emerging mechanistic insights into how the virus triggers brain damage, are raising the prospect of treating or preventing MS.
These advances come at a time when researchers are more interested than ever in what happens in the months and years following a viral infection, and highlights the issues untangling the relationships between infectious diseases and chronic conditions.
This is an audio version of our Feature: The quest to prevent MS — and understand other post-viral diseases.
Hosted on Acast. See acast.com/privacy for more information.